Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Performance Based
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(106)
•••
Comment by G1945Von May 19, 2024 8:26am
85 Views
Post# 36047787

RE:RE:RE:RE:RE:Performance Based

RE:RE:RE:RE:RE:Performance Based
M101 wrote: You should google Hans Black  about that SEDI info, goes back to the Amorfix days.

I don't know about the current ownership stats and have assumed it doesn't matter because an arms-length investor group is all that's needed to hold control while avoiding reporting requirements.

Also, 19 million shares at $1.88 = 35.7 mil cap= just enough to satisfy Nasdaq rule 5550(b), so that's probably why they picked that price and why it will continue to show resistance.  You don't need to know who's in control to recognize control. 
   


 
  


So can I say that Hans Peter Black is allegedly a bit of a shady character?

https://www.sec.gov/litigation/litreleases/lr-23713

Do you have any idea why SEDI info shows a common share count of over 34 million shares for ProMis Neurosciences Inc.?

I just learned that "Interinvest Corporation Inc." is owned and controlled by Hans Peter Black. 


G1945V
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities